Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

EU Commission launches AMR Action Plan
The action plan addresses resistance in both humans and animals.
Plan address resistance in humans and animals 

A new action plan to tackle antibiotic resistance (AMR) has been launched by the European Commission.

Underpinned by a One Health approach, the action plan addresses resistance in both humans and animals. It foresees more than 75 actions built on three main pillars:

    •    Make Europe a best practice region
    •    Boost research, development and innovation
    •    Shape the global agenda

The first deliverable of the plan, EU Guidelines on the prudent use of antimicrobials in human health, has already been adopted by the Commission.  

“Antimicrobial Resistance is a global growing threat, and if we do not step up our action and commitment now, by 2050 it could cause more deaths than cancer,” commented Vytenis Andriukaitis, commissioner for health and food safety.

“The ambitious agenda I present today focuses actions on key areas with the highest added value for EU countries. By promoting prudent use of antimicrobials in people and animals, consolidating surveillance, improving data collection and boosting research, I aim to make the EU a best practice region worthy of shaping the global agenda on AMR in this increasingly interconnected world”.

Pillar one of the plan is making the EU a best-practice region. This will require better evidence, better coordination and surveillance, in addition to better control measures. This will support Member States to establish, implement and monitor their national One Health Action Plans on AMR made at the 2015 World Health Assembly.

Actions under pillar two aim to boost research and further incentivise innovation. The Commission will work with Member States and industry to address AMR in bacteria, fungi and parasites. Special attention will be given to the WHO priority list of pathogens as well as tuberculosis, HIV/AIDS, malaria and neglected infectious diseases.

Pillar three focuses on shaping the global agenda. The EU will work towards reinforcing engagement and collaboration with multilateral organisations, and intensifying cooperation with the most affected developing countries.
 
“We need a truly European research effort to save human lives, animals and the environment,” added Carlos Moedas, commissioner for research, science and innovation. “That's why the One Health Action Plan is so important – it will mean better research coordination and collaboration between EU Member States, as well as public and private sectors across Europe and beyond".

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.